Which riddles around hepatic regeneration can we foresee answering in the future as the capabilities around single-cell genomics and its successors continue to expand rapidly?
This episode focuses on the history of single-cell genomics up through spatial transcriptomics and beyond and raises questions about the new things we can learn and the demand these improved techniques place on other elements in the research process.
What are the implications of the targeted NASH therapies of the future on NASH drug development today?
Scott Friedman discusses that background for the potential breakthrough work from Jon Epstein at the University of Pennsylvania on how combined mRNA/CAR-T therapy can regress fibrosis in mouse CVD models.
